Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Novartis ag    crawled time : 13:35    save search

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
Published: 2021-04-06 (Crawled : 13:35) - biospace.com/
NVS | News | $98.67 0.33% 260K twitter stocktwits trandingview |
Health Technology
| | O: -0.41% H: 0.67% C: -0.63%

covid phase 2 molecular trial ensovibep
Gainers vs Losers
46% 54%

Top 10 Gainers
SGBX | $0.26 80.43% 54M twitter stocktwits trandingview |
Producer Manufacturing

LICN | $1.0 78.57% 3.3M twitter stocktwits trandingview |

CSSE 4 | $0.2656 74.39% 9.7M twitter stocktwits trandingview |
Consumer Services

BRFH 4 | $1.89 71.82% 32M twitter stocktwits trandingview |
Manufacturing

ACON | $0.49 70.14% 24M twitter stocktwits trandingview |
n/a

BOF | $1.95 66.67% 920K twitter stocktwits trandingview |

MTC | $3.62 61.61% 790K twitter stocktwits trandingview |
Technology Services

AMST | $3.22 61.0% 720K twitter stocktwits trandingview |
Technology Services

PCSA | $2.28 40.74% 37M twitter stocktwits trandingview |
Producer Manufacturing

EVA | $0.626 39.14% 2.3M twitter stocktwits trandingview |
Process Industries


Your saved searches
Save your searches and get alerts when important news are released.